Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.6%

Eli Lilly and Company (NYSE:LLY)’s share price fell 1.6% during mid-day trading on Wednesday . The company traded as low as $731.20 and last traded at $733.85. 672,630 shares were traded during mid-day trading, a decline of 78% from the average session volume of 3,019,784 shares. The stock had previously closed at $745.69.

Analysts Set New Price Targets

A number of equities analysts recently commented on LLY shares. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Morgan Stanley upped their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Trading Down 1.0 %

The company has a 50-day moving average price of $762.75 and a 200 day moving average price of $664.94. The firm has a market cap of $688.74 billion, a price-to-earnings ratio of 124.98, a PEG ratio of 1.60 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the firm earned $2.09 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

Several large investors have recently made changes to their positions in the stock. Aurora Private Wealth Inc. increased its position in shares of Eli Lilly and Company by 24.2% during the third quarter. Aurora Private Wealth Inc. now owns 893 shares of the company’s stock valued at $479,000 after purchasing an additional 174 shares during the period. Culbertson A N & Co. Inc. acquired a new stake in Eli Lilly and Company in the third quarter worth $216,000. DeDora Capital Inc. increased its stake in Eli Lilly and Company by 23.5% during the 3rd quarter. DeDora Capital Inc. now owns 1,732 shares of the company’s stock worth $930,000 after purchasing an additional 330 shares in the last quarter. Goldstein Advisors LLC lifted its stake in Eli Lilly and Company by 6.0% in the 3rd quarter. Goldstein Advisors LLC now owns 563 shares of the company’s stock valued at $302,000 after acquiring an additional 32 shares in the last quarter. Finally, SS&H Financial Advisors Inc. bought a new stake in Eli Lilly and Company during the 3rd quarter worth about $450,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.